Business Wire

Aegerion’s Myalepta®▼ Approved in Europe : the First Treatment Indicated for Patients with Ultra-Rare Disease, Lipodystrophy

Del

Aegerion Pharmaceuticals today announced the granting of a marketing authorisation in Europe for Myalepta (metreleptin) by the European Commission. Myalepta is a treatment for the ultra-rare condition, lipodystrophy, and has been approved as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients. With this authorisation, Myalepta becomes the first and only licensed medication to treat the underlying leptin deficiency at the heart of this ultra-rare condition.

Professor Sir Stephen O’Rahilly, Professor of Clinical Biochemistry and Medicine at Addenbrooke’s Hospital, Cambridge, said, “Lipodystrophy is a rare condition which, due to its complex nature, requires highly specialised treatment. Patients with lipodystrophy have previously relied on lifestyle changes and medications, like insulin injections to manage the condition’s associated complications. Today’s milestone marks a significant change in the way lipodystrophy is treated. For the first time, we will be able to offer patients in Europe a treatment option that addresses one of the fundamental aspects of the condition itself.”

Rebecca Sanders, Founder and Chair of Lipodystrophy UK, said, “Lipodystrophy presents multiple ongoing challenges, both physical and psychological, to individuals living with the condition. Current available treatment options have been limited, address only some of the complications of the condition and are not specialised for lipodystrophy. Myalepta offers a long-term solution for patients and we are delighted that there is now a treatment available specifically to treat the complications of leptin deficiency in lipodystrophy which will give patients a much needed option to help improve both their disease and their quality of life.”

Lipodystrophy is an ultra-rare and incurable disease which impacts a person’s ability to store fat in their body, and can either be generalised (GL) or partial (PL).1 The condition is associated with a number of critical metabolic problems, such as severe diabetes, and can cause severe organ damage if uncontrolled.2 Globally, lipodystrophy affects approximately between 1 and 4 people per million.1

Paul Greenland, President EMEA at Aegerion Pharmaceuticals, said, “We are thrilled that patients with lipodystrophy in Europe will now have a specific treatment option. This also represents an exciting time for Aegerion as Myalepta becomes available in one of the largest global pharmaceutical markets. We will work collaboratively with patient organisations, health care professional and health services across Europe to enable access to as many patients as possible.”

#ENDS#

NOTES TO EDITORS

Data supporting approval of Myalepta

The safety and efficacy of Myalepta for the treatment of metabolic disorders, associated with lipodystrophy syndromes in pediatric and adult patients, were evaluated in a long-term, open-label, single-arm study conducted under the auspices of the National Institutes of Health (NIH) in the United States.

The observed primary efficacy results in patients with generalised lipodystrophy were:

  • A mean change from baseline to month 12 in HbA1c* of -2.2%; and
  • A mean percent change from baseline to month 12 in triglyceridesof -32.1%.3

In addition, 41% (16 of 39) of GL patients on insulin at baseline were insulin-free following treatment, 22% (7 of 32) of GL patients on oral anti-diabetic agents at baseline were able to discontinue, and 24% (8 of 34) of GL patients on lipid-lowering therapies at baseline were able to discontinue use of these therapies during Myalepta treatment.4

The observed primary efficacy results in the PL subgroup patients were:

  • A mean change from baseline to month 12 in HbA1c of -0.9%; and
  • A mean percent change from baseline to month 12 in triglycerides of -37.4%.3

The most frequently occurring adverse reactions from the clinical studies were hypoglycaemia (14%) and weight decreased (17%). Other common side effects (occurring inbetween 1 to 10% of patients) were decreased appetitite, headache, abdominal pain, nausea, alopecia, menorrhagia, fatigue, injection site bruising/erythema/reactions, neutralising antibody formation**.3

About lipodystrophy

Lipodystrophy is an ultra-rare condition that is characterised by the irreversible loss of adipose tissue.1 In patients with lipodystrophy, the lack of adipose tissue results in a loss of leptin production. Leptin is a naturally occurring hormone produced by subcutaneous fat and is an important regulator of energy homoeostasis, fat and glucose metabolism, reproductive capacity, and other diverse physiological functions.5

Lipodystrophy can be genetic or acquired after an immune condition and occurs in childhood or adolescence.6 Generalised lipodystrophy is a complete lack of fat affecting the whole body.7 Partial lipodystrophy is typically associated with a lack of fat in the arms, legs, head, and trunk regions while fat can accumulate in other areas of the body, including the neck, face and intra-abdominal regions affecting vital organs like the liver and heart.7

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a Novelion Therapeutics Inc. company: a biopharmaceutical company dedicated to developing and commercialising innovative new therapies for individuals living with rare and orphan diseases. Aegerion was acquired by Novelion Therapeutics Inc. in November 2016. The company’s European headquarters are situated in Windsor, UK.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Adverse events can be reported to Aegerion at

00800 23437466 or at medinfo.emea@aegerion.com

* HbA1c is a standard test used to measure an individual’s average blood sugar levels

Triglycerides are a type of fat in the blood

** Refer to the SmPC for a full list of adverse reactions (provided with this press release)

References

1 Chiquette, E., et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes, 2017. 10: p.375-383.

2 Pope, E., et al., Childhood acquired lipodystrophy: A retrospective study. Journal of the American Academy of Dermatology, 2006. 55(6): p. 947-950.

3 SmPC EMEA. Myalepta 11.3 mg powder for solution for injection. (provided with this document).

4 Brown, RJ., et al., Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine, 2018. 60(3): p.479-489.

5 Kelesidis, T., et al., Narrative Review: The Role of Leptin in Human Physiology: Emerging Clinical Applications. Ann Intern Med, 2010. 152(2): p.93–100.

6 Brown, R.J., et al., The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab, 2016. 101(12): p. 4500-4511.

7 Fiorenza, C.G., et al., Lipodystrophy: Pathophysiology and Advances in Treatment. Nat Rev Endocrinol, 2011. 7(3): p. 137-150.

Contact information

Aegerion Pharmaceuticals
Charlotte Dawkins
Consultant, Patient Advocacy and Communications
07932 722950
charlotte.dawkins@aegerion.com
or
Harriet Reynolds
Senior Account Manager
Reynolds-MacKenzie
07384 438631
HarrietR@ReynoldsMackenzie.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)21.9.2018 22:13Pressemelding

Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced

Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 17:43Pressemelding

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar

Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41Pressemelding

Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo

Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46Pressemelding

The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+

Asda Selects HCL Technologies to Help Drive IT Transformation21.9.2018 12:16Pressemelding

HCL Technologies (HCL), a leading global technology company, today announced that it has been selected to help drive IT transformation at the UK’s third-largest grocery retailer, Asda. The three-year application services contract will see HCL transform Asda’s IT Application Services with a new DevOps delivery model to drive data and analytics and support back-office applications through the full lifecycle of development, testing and support. HCL will also build a central data management platform to enable Asda to improve its insight and analytics capabilities. Asda operates more than 600 stores across the UK, employing over 135,000 people. Asda wanted to adopt a more agile approach towards application development and testing. This would allow the company to respond faster to business requirements and reduce time to market, while driving better user experience and satisfaction. HCL was selected due to its extensive expertise in successfully delivering similar large scale IT transformati